key: cord-1032781-9tvu1o87
authors: Tsuji, Genichiro; Yonemitsu, Kenzo; Ito, Takahito; Yanase, Yuta; Uema, Masashi; Ohoka, Nobumichi; Inoue, Takao; Asakura, Hiroshi; Demizu, Yosuke
title: Development of ciclesonide analogues that block SARS-CoV-2 RNA replication
date: 2021-04-20
journal: Bioorg Med Chem Lett
DOI: 10.1016/j.bmcl.2021.128052
sha: e4857965c5e9a413b7340336672a80d4da29be26
doc_id: 1032781
cord_uid: 9tvu1o87

Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity.

Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing 4 clinical trials for treatment of coronavirus disease 2019 . An active 5 metabolite of ciclesonide, Cic2, was recently reported to repress severe acute 6 respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, 7 we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an 8 azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral 9 replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). 10 These compounds are promising as novel therapeutic agents for COVID-19 that show 11 significant antiviral activity. Remdesivir has been approved in some countries for treatment of COVID-19, and 10 decreases viral replication by inhibiting the polymerase. 3 Although no nuclease 11 inhibitors against SARS-CoV-2 have yet been approved for COVID-19 treatment, it 12 was recently reported that ciclesonide (Cicle), an approved drug for treatment of 13 steroidal asthma, is its promising candidate. 4, 5 Cicle activity depends on hydrolysis by 14 esterases to yield the active metabolite Cic2 (Figure 1) , and Cic2 was reported to 15 repress SARS-CoV-2 genomic RNA replication. 4 

In this report, we investigated the potential of Cic2 derivatives with the expectation that 17 replacing the primary hydroxy group of the active metabolite with other functional 18 groups Cic3-Cic10 would improve efficacy. In addition, viral growth inhibition and 19 cytotoxicity of the synthesized analogues were evaluated. The synthetic route for those analogues is shown in Scheme 1. Briefly, Cic2 with was 5 converted to the mesylated Cic3. 5 Then, Cic4 (bearing an azide group) and Cic10 6 (bearing an amino group) were obtained from Cic3. The analogue Cic5, in which the 7 ester group of Cic1 was replaced with an amide group, was synthesized from Cic10. 8 The compounds Cic6 (bearing a chloro group), Cic7 (bearing a bromo group), and Cic8 9 (bearing an iodo group) were synthesized from the mesylated Cic3. 5 The Cic9 analogue, 10 bearing a dimethylamino group, was prepared by treating Cic7 with dimethylamine. The synthesized compounds were incubated with Vero E6/TMPRSS2 cells for 18 hours 2 and cytotoxicity was evaluated via release of lactate dehydrogenase (LDH). 6 The 3 prodrug Cicle, Cic4 (bearing an azide group), Cic5 (an amide-type Cicle), and Cic6 4 (bearing a chloro group) did not show significant cytotoxicity at concentrations up to 40 5 µM. In contrast, the active metabolite Cic2, Cic3 (bearing a methanesulfonyl group), 6 and Cic10 (bearing an amino group) were cytotoxic at concentrations above 20 µM. showed no cytotoxicity (Figure 2) , had more pronounced effects on reduction of the 10 viral RNA than Cicle (2.1×10 5 copies/well and 4.6×10 5 copies/well, respectively, concentrations of these compounds. 6 As shown in Figure 4 , Cicle, Cic2, Cic4, and (bearing an azide group) and Cic6 (bearing a chloro group) showed potent reduction of 10 viral replication and low cytotoxicity compared with Cic2. The low cytotoxicity and 11 strong antiviral activity of these compounds is a new discovery, and we hope that the 12 results of our study will serve as a stepping stone for the development of effective 13 therapeutics against SARS-CoV-2 and other viruses. The detailed structure-activity 14 relationship between Cic4 and Cic6 is difficult to describe at this stage because target 9 1 molecules (proteins) of Cicle compounds are not yet found. However, Cic4 and Cic6 2 are less polar than Cic2, Cic9 and Cic10, therefore, they may enter the cells more 3 easily. Cic4 and Cic6 are also less reactive than Cic3, Cic7 and Cic8, so they may be 4 less degraded and less likely to react with intracellular molecules. Recently, it was 5 reported that Cicle inhibited SARS-CoV-2 replication but resistance mutations mapped 6 to viral nonstructural protein 3 (nsp3) and nsp4. 4 Considering the report, further 7 biological assays are needed to understand the potent activity of the ligands Cic4 and 8 Cic6, including search for their target proteins and evaluation of their binding activity, 9 and evaluation of their chemical stability. Elucidation of those evaluation and further 10 structural expansion starting from the azide group of Cic4 (e.g., using click chemistry) 11 are underway. 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

declare the following financial interests/personal relationships which may be 16 considered as potential competing interests